期刊文献+

生物样本库质量控制体系在冠心病中的初步应用 被引量:2

Discussion of Biosample quality management in CAD Biobank
下载PDF
导出
摘要 目的探讨老年病生物样本库建立质量控制体系在老年冠心病中的应用研究。方法制定老年病样本库操作流程及质量控制体系,规范化收集、处理及保存诊断为老年冠心病的血液标本380例,进行生化指标测定、血浆及全血基因组DNA提取,并检测DNA的浓度和纯度,同时建立一套信息管理系统用于老年冠心病生物样本库的管理。结果 380例有完整临床资料的老年冠心病患者的全血标本、血浆及DNA的提取成功率均为100%,并随机抽取20份DNA进行质量检测,结果表明所收集标本质量较好。初步建立了规范化的样本信息资料软件管理系统。结论该研究有效的在老年冠心病中建立了标准化的质量控制系统并加以应用研究,为冠心病研究提供规范化的临床样本资源平台。 Objective To discuss the establishment of standardized operation procedure and quality control system of blood specimens from patients with CAD in Biobank. Methods An information management system and the operational processes system in CAD Biobank for blood sample collection, quality control system were developed. Whole blood samples were collected from 380 patients whom were all diagnosed with CAD. Plasma and whole blood genomic DNA was extracted from the specimens, and the purity and concentration of DNA were determined. Results Blood samples of 380 CAD patients were collected. 20 were randomly selected for DNA and RNA quality control testing. The success rate was 100% for extraction of plasma and whole -blood genomic DNA. The results showed these collected specimens had high quality. Conclusion The quality control system of CAD Biobank has been successfully established in this study. Development of standardized information management and quality control of specimens is helpful to improve the efficiency of CAD sample quality
出处 《老年医学与保健》 CAS 2016年第1期28-31,共4页 Geriatrics & Health Care
关键词 生物样本库 冠心病 质量控制体系 个体化医学 Biobank Coronary heart disease Biosample quality management Personalized medicine
  • 相关文献

参考文献2

二级参考文献54

  • 1季加孚.北京大学临床肿瘤学院标本库的建设[J].北京大学学报(医学版),2005,37(3):329-330. 被引量:81
  • 2US Department of Health and Human Services, Food and Drug Administration. Challenge and opportunity on the critical path to new medical products [ EB/OL]. (2004-03-16). http://www. fda. gov/ScienceResearch/SpecialTopics/CriticalPathIntiative/Cri- ticalPathOpportunitiesReports/. UCM0771262. htm.
  • 3US Department of Health and Human Services, Food and Drug Administration. Critical path opportunities report [ EB/OL ]. (2006-03). http ://www. fda. gov/ScienceResearch/SpecialTopics/ CriticalPathIntiative/CriticalPathOpportunitiesReports/. UCM077- 254. pdf.
  • 4Vaught J, Rogers J, Myers K, et al. An NCI perspective on creating sustainable biospecimen resources. J Natl Cancer Inst Monogr, 2011,42:1-7.
  • 5Vgv6ri , Welinder C, Lindberg H, et al. Biobank resources for future patient care:developments, principles and concepts. J Clin Bioinforma, 2011,1:24.
  • 6Merrero JA, Henley KS. The role of serum biomarkers in hepatocellular carcinoma surveillance. Gastroenterol Hepatol, 2011,7:821-823.
  • 7Franco JR, Simarro PP, Diarra A, et al. The human African trypanosomiasis specimen biobank: a necessary tool to support research of new diagnostics. PLoS Negl Trop Dis, 2012,6:e1571.
  • 8DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new esimates of drug development costs. J Health (NY) Econ, 2003,22 : 151-185.
  • 9Khleif SN, Doroshow JH, Hait WN, et al. AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report:advancing the use of biomarkers in cancer drug development. Clin Cancer Res, 2010,16:3299-3318.
  • 10Chau CH, Rixe O, McLeod H, et al. Validation ot analytical methods for biomarkers employed in drug development. Clin Cancer Res, 2008,14:5967-5976.

共引文献31

同被引文献11

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部